Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0782
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2627
    +0.0005 (+0.04%)
     
  • USD/JPY

    151.3320
    -0.0400 (-0.03%)
     
  • Bitcoin USD

    69,966.78
    -892.95 (-1.26%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Boehringer eyes marked sales gain, boosted by animal health

INGELHEIM, Germany, April 5 (Reuters) - Boehringer Ingelheim, Germany's second-largest drugmaker, said on Wednesday it was targeting a marked gain in 2017 revenues, boosted by new animal health businesses it acquired from Sanofi.

Unlisted Boehringer on Jan. 1 wrapped up an asset swap that saw Boehringer take Sanofi's $13.5 billion animal care subsidiary, making it Europe's largest player in the industry.

In return, Sanofi obtained the German company's consumer health care business unit, valued at nearly $8 billion, plus a $5.5 billion cash payment from Boehringer.

Boehringer, which invented mass production of baking powder in the 1890s and which collaborates on diabetes drugs with Eli Lilly, posted a 7.1 percent gain in sales to 15.9 billion euros ($17.0 billion) last year.

Operating income jumped 27 percent to 2.9 billion euros, helped by an upfront payment of almost $600 million from U.S. drugmaker AbbVie for the marketing rights to a promising experimental psoriasis treatment.

($1 = 0.9368 euros) (Reporting by Patricia Weiss; Writing by Ludwig Burger; Editing by Maria Sheahan)

Advertisement